|Day Low/High||287.47 / 292.30|
|52 Wk Low/High||244.28 / 370.57|
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer's and Parkinson's Therapies, an AAT-AD/PD Focus Meeting.
Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc.
TPX, WR, GOV, BIIB and SRE were all recently were downgraded by TheStreet's Quant Ratings service.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38 th Annual Health Care Conference.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AC, BJRI, SUN, UNT Downgrades: AAC, BELFA, BIIB, BMCH, EIX, GXP, KMX, LAWS, LUK, MUX, RPXC, TPX, VDSI, WR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Biogen (Nasdaq: BIIB) announced today that in the Phase 2b dose-ranging ACTION 2 study in individuals with acute ischemic stroke (AIS), natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 7th Annual Global Healthcare Conference.
Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.
The biotech sector has seen a big rally, but there are still opportunities.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Here's what you need to know now for Thursday, Jan. 25
Stocks come off early highs after Caterpillar shares trade lower.
U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.
Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including: Full year total revenues of $12.
Consumer spending should be more than solid given wage increases.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.
U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.
France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.
Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.